Yes, injection site selection is important for GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)
A Reddit thread pointed me to the gray market: a compounding pharmacy still shipping despite new regulatory pressure
Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy
The proposed mechanisms by which GLP-1 agonists may reduce alcohol consumption involve complex interactions within the brain's reward circuitry
Production of metabolites from amino acids, however, could play an important role in GLP-1 secretion from the colon, as the microbiota can ferment nutrients reaching the distal intestine (mostly colon) and produce metabolites, which may stimulate GLP-1 and PYY secretion [36,37,38]
A patient may therefore still be in an escalation period around month 3, depending on the prescription and tolerability